Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
96 people get GPRO articles and Market Currents by email alert.
Get email alerts on GPRO »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (Jul 31, 2012)
-
PR Newswire (Jul 24, 2012)
-
Review Of Analyst Upgrades This Week - Part VIThe Value Investor • Mon, May 28, 2012
-
PR Newswire (May 8, 2012)
-
PR Newswire (May 3, 2012)
-
Hologic Must Make The Third Time A CharmStephen Simpson • Tue, May 1, 2012
-
Gen-Probe's CEO Discusses Q1 2012 Results - Earnings Call TranscriptMon, Apr 30, 2012
-
PR Newswire (Apr 30, 2012)
-
PR Newswire (Apr 26, 2012)
-
PR Newswire (Apr 13, 2012)
-
PR Newswire (Mar 12, 2012)
-
Gen-Probe Looking To New Launches To Drive MomentumStephen Simpson • Tue, Feb 14, 2012
To learn more about Seeking Alpha Pro, click here.
-
Gen-Probe Looking To New Launches To Drive MomentumStephen Simpson • Tue, Feb 14, 2012
-
FDA Approves Gen-Probe AssayZacks Investment Research • Thu, Nov 26, 2009
-
Review Of Analyst Upgrades This Week - Part VIThe Value Investor • Mon, May 28, 2012
-
Hologic Must Make The Third Time A CharmStephen Simpson • Tue, May 1, 2012
-
Becton Dickinson Too Beloved For NowStephen Simpson • Tue, Feb 7, 2012
-
Skepticism Still Working For Hologic InvestorsStephen Simpson • Tue, Jan 31, 2012
-
7 Best Healthcare Stocks For 2012 According To BarclaysInsider Monkey • Mon, Dec 19, 2011
-
9 Of Richard F. Aster's Q2 Stock HoldingsDividend Screen • Tue, Sep 6, 2011
-
Monday Options RecapFrederic Ruffy • Mon, Jun 6, 2011
-
Thursday Options RecapFrederic Ruffy • Thu, May 19, 2011
-
Gen-Probe's CEO Discusses Q1 2012 Results - Earnings Call TranscriptMon, Apr 30, 2012
-
Gen-Probe's CEO Discusses Q4 2011 Results - Earnings Call TranscriptMon, Feb 13, 2012
-
Gen-Probe's CEO Discusses Q3 2011 Results - Earnings Call TranscriptWed, Nov 2, 2011
-
Gen-Probe's CEO Discusses Q2 2011 Results - Earnings Call TranscriptThu, Jul 28, 2011
-
Gen-probe Q3 2009 Earnings Call TranscriptFri, Oct 30, 2009
-
Gen Probe, Inc., Q4 2008 Earnings Call TranscriptTue, Feb 17, 2009
-
Gen-Probe Inc. Q3 2008 Earnings Conference Call TranscriptFri, Oct 31, 2008
-
Gen-Probe, Inc. Q2 2008 Earnings CallThu, Jul 31, 2008
-
Gen Probe Incorporated Q1 2008 Earnings Call TranscriptTue, Apr 29, 2008
-
Gen-Probe, Inc. Q4 2007 Earnings Call TranscriptWed, Feb 13, 2008
-
Gen-Probe Inc. Q3 2007 Earnings Call TranscriptTue, Oct 30, 2007
-
Gen-Probe Q2 2007 Earnings Call TranscriptWed, Aug 1, 2007
-
Gen-Probe Q1 2007 Earnings Call TranscriptTue, May 1, 2007
-
Gen-Probe Q4 2006 Earnings Call TranscriptTue, Feb 13, 2007
-
Gen-Probe Q3 2006 Earnings Call TranscriptWed, Nov 1, 2006
-
Gen-Probe Q4 2005 Earnings Conference Call Transcript (GPRO)Mon, Feb 20, 2006
-
PR Newswire (Jul 31, 2012)
-
at MarketWatch.com (Jul 26, 2012)
-
PR Newswire (Jul 24, 2012)
-
PR Newswire (May 8, 2012)
-
PR Newswire (May 3, 2012)
-
at CNBC.com (Apr 30, 2012)
-
at MarketWatch.com (Apr 30, 2012)
-
at MarketWatch.com (Apr 30, 2012)
-
PR Newswire (Apr 30, 2012)
-
PR Newswire (Apr 26, 2012)
-
PR Newswire (Apr 13, 2012)
-
PR Newswire (Mar 12, 2012)
-
at MarketWatch.com (Feb 8, 2012)
-
PR Newswire (Jan 27, 2012)
-
PR Newswire (Jan 9, 2012)
-
PR Newswire (Jan 4, 2012)
-
PR Newswire (Dec 9, 2011)
-
at MarketWatch.com (Sep 29, 2011)
-
at CNBC.com (Jun 7, 2011)
-
at MarketWatch.com (Jun 6, 2011)
GPRO vs. ETF Alternatives
Company Description
Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests, or NATs, used primarily to diagnose human diseases and screen donated human blood. NATs are designed to detect diseases more rapidly... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, July 11, 2012, 5:13 PM Hologic (HOLX) falls slightly AH after: 1) Announcing a $750M debt offering and $3.05B worth of credit facilities to finance its $3.7B acquisition of Gen-Probe (GPRO). 2) Stating the Gen-Probe acquisition is on track to close around August 1. 3) Pre-announcing FQ3 (ended in June) revenue of $470M and EPS of $0.34-$0.35, which compares with a consensus of $477.5M and $0.34. 4) Reaffirming its FY12 guidance. Comment! [Healthcare, Earnings, M&A]
- Thursday, June 28, 2012, 11:41 AM Piper Jaffray says the Supreme Court's decision is positive for companies exposed to doctors' offices, with Genomic Health (GHDX -0.8%) likely the biggest beneficiary. Other names that should benefit include: Gen-Probe (GPRO +0.1%), Hologic (HOLX -1.6%), Qiagen (QGEN -1.8%), EXACT Sciences (EXAS -2.8%) and Meriad Genetics (MYGN +0.2%). Comment! [Healthcare, On the Move]
- Monday, June 18, 2012, 2:49 PM Jefferies says Hologic's (HOLX +1.2%) pending acquisition of Gen-Probe (GPRO +0.5%) could be a significant earnings driver for the combined company. The firm believes the combination could generate $2.68 in EPS including almost $1.00 in incremental earnings by FY15. Jefferies says HOLX is very attractive at current levels and reiterates a Buy on the name with a $24 price target. Comment! [Healthcare, On the Move]
- Monday, May 14, 2012, 12:54 PM Hologic (HOLX +1.6%) ticks higher after JPMorgan ups the shares to Overweight. The firm says the upgrade was made to reflect compelling risk/reward and synergies from the Gen-Probe (GPRO) deal. Its price target is also raised to $22 from $20. Comment! [Healthcare, On the Move]
- Monday, April 30, 2012, 10:49 AM Hologic (HOLX) -9.8% following news it's to pay ~$3.7B for Gen-Probe (GPRO), which skies 18.%. While Piper Jaffray's Bill Quirk says that "strategically, this makes all the sense in the world," Dougherty's Junaid Husain is very cautious. Because Gen-Probe is mature, "I am just not sure where they are going to get the accelerated growth." Comment! [M&A, Healthcare, On the Move]
-
Monday, April 30, 2012, 9:10 AM
Premarket gainers: BKS +92%. DMD +38%. SUN +21%. WCRX +20%. GPRO +20%. XOMA +9%. IOC +5%. MNKD +5%. PLX +4%. ARNA +4%. AMRN +3%.
Losers: LDK -14%. SOHU -8%. GNC -5%. HUM -5%. HOLX -4%. SINA -3%. Comment! [On the Move] - Monday, April 30, 2012, 7:55 AM Hologic (HOLX) agrees to acquire Gen-Probe (GPRO) for ~$3.7B in cash, in the pairing of two smidcap healthcare diagnostics companies. GPRO investors will receive $82.75/share, ~20% above its April 27 closing price. GPRO’s molecular diagnostic products include tests for chlamydia and gonorrhea, as well as human papillomavirus. GPRO +19.3%, HOLX +4.8% premarket. Comment! [Healthcare, M&A, On the Move]
- Monday, April 30, 2012, 7:13 AM Gen-Probe (GPRO): Q1 EPS of $0.55 beats by $0.04. Revenue of $150M (+7.3% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Monday, February 13, 2012, 4:17 PM Gen-Probe (GPRO): Q4 EPS of $0.72 beats by $0.04. Revenue of $158.2M (+15.7% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Monday, February 13, 2012, 12:10 AM Notable earnings after Monday's close: FIS, GPRO, HMA, LPS, MAS, RAX, RGC, SGEN Comment! [Earnings]
- Sunday, February 12, 2012, 5:35 PM Notable earnings after Monday's close: FIS, GPRO, HMA, LPS, MAS, RAX, RGC, SGEN 1 Comment [Earnings]
- Monday, December 19, 2011, 8:23 AM Deutsche Bank initiates coverage on Gen-Probe (GPRO) with a Buy rating and $70.50 price target. Analysts with the firm see Gen-Probe as a leading player in the +$4.5B MDx market with a promising FY12 pipeline set to help it add product momentum and low double-digit revenue growth Comment! [Healthcare, Quick Ideas]
- Monday, October 3, 2011, 3:30 PM It's been a wild ride today for pharmaceutical developer Vermillion (VRML), jumping +19% at the open on positive preliminary results for its PAD drug Vasclir, only to reverse course and tumble -13% as the biotech sector continues to collapse. Other biotech shares getting hit today: Cerus (CERS -5.2%), EXACT Sciences (EXAS -5.2%), Quest Diagnostics (DGX -5.2%), Gen-Probe (GPRO -3.8%), and (CPHD -2.6%). Comment! [Healthcare, On the Move]
- Tuesday, September 6, 2011, 2:52 PM Gen-Probe (GPRO +2.4%) gains on a valuation upgrade to speculative buy at Canaccord, citing its new product cycle and strong sector leadership position. Comment! [On the Move]
- Tuesday, July 19, 2011, 1:29 PM Gen-Probe (GPRO) -3% on reports that Novartis is no longer pursuing an acquisition. Comment! [Breaking News, On the Move, Healthcare]
- Tuesday, July 5, 2011, 10:16 AM TPG's acquisition of Immucor (BLUD +30%) fails to spur comparables Bio-Rad Laboratories (BIO -0.7%) and Gen-Probe (GPRO -1.1%). Takeout multiples were below current diagnostics multiples, Leerink notes, and the P-E buyout likely means there was little interest in BLUD from strategic acquirers. 1 Comment [Healthcare, M&A, On the Move, Quick Ideas]
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.






